Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Diabetes mellitus type 2 Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The treatment must be used in combination with at least one of: metformin, a sulfonylurea, insulin, AND The condition must be inadequately responsive to at least one of: metformin, a sulfonylurea, insulin. Treatment criteria: Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another DPP4 inhibitor.
“Alogliptin is a potent (IC50 around 7nM) and highly selective (>10,000 fold selectivity versus DPP-8 or DPP-9), reversible, competitive inhibitor of DPP-4, an enzyme that rapidly degrades incretin hormones.”
“The recommended daily dose of NESINA 25 mg was eliminated with a mean terminal half-life (T 1/2 ) of approximately 21 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin. In vitro studies indicate that alogliptin does not induce CYP1A2, CYP2B6, CYP2C9, CYP2C19 or CYP3A4 and does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin.”